{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:42:23Z","timestamp":1790991743548,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Heart failure (HF) remains one of the most common diseases and one of the major causes of death worldwide. HF is often associated with other chronic diseases, most commonly with anemia. Anemia increases patients' mortality and lowers their quality of life. There are a few pathophysiological mechanisms that explain anemia in patients with HF \u2013 hemodilution, absolute or functional iron deficiency, activation of the inflammatory cascade, chronic kidney disease, and impaired erythropoietin production and activity. Moreover, congestive HF is often treated with angiotensin-converting enzyme inhibitors and aldosterone receptors blockers, which could be linked to the development of anemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/heartviews.heartviews_211_20","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T04:14:37Z","timestamp":1633925677000},"page":"196-200","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Anaemia in Heart Failure Patients, Associated with Angiotensin \u2013 Renin \u2013 Aldosterone System Altering Medications"],"prefix":"10.4103","volume":"22","author":[{"given":"Neda","family":"Jonaitien\u0117","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gryt\u0117","family":"Ramantauskait\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Laukaitien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-5-20240902","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.hlc.2015.06.827","article-title":"Iron deficiency in heart failure: Looking beyond anaemia","volume":"25","author":"Wong","year":"2016","journal-title":"Heart Lung Circ"},{"key":"R4-5-20240902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/246915","article-title":"Anemia in heart failure patients","volume":"2012","author":"Alexandrakis","year":"2012","journal-title":"ISRN Hematol"},{"key":"R5-5-20240902","doi-asserted-by":"crossref","first-page":"R808","DOI":"10.1152\/ajpregu.00250.2009","article-title":"Separate mechanisms cause anemia in ischemic vs.nonischemic murine heart failure","volume":"298","author":"Iversen","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R6-5-20240902","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/eurheartj\/ehl419","article-title":"Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well","volume":"28","author":"Westenbrink","year":"2007","journal-title":"Eur Heart J"},{"key":"R7-5-20240902","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.hfc.2010.03.002","article-title":"Pathophysiology of anemia in heart failure","volume":"6","author":"Anand","year":"2010","journal-title":"Heart Fail Clin"},{"key":"R8-5-20240902","doi-asserted-by":"crossref","first-page":"E329","DOI":"10.3390\/medicina55070329","article-title":"The influence of cardiovascular medications on iron metabolism in patients with heart failure","volume":"55","author":"Sirbu","year":"2019","journal-title":"Medicina (Kaunas"},{"key":"R9-5-20240902","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1524-6175.2004.02866.x","article-title":"Angiotensin-converting enzyme inhibitors side effects--Physiologic and non-physiologic considerations","volume":"6","author":"Sica","year":"2004","journal-title":"J Clin Hypertens (Greenwich"},{"key":"R10-5-20240902","first-page":"1169","article-title":"Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: A review. III. Angiotensin-converting enzyme inhibitors","volume":"27","author":"Ascen\u00e7\u00e3o","year":"2008","journal-title":"Rev Port Cardiol"},{"key":"R11-5-20240902","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00041552-200109000-00008","article-title":"The heart outcomes prevention evaluation study: Angiotensin-converting enzyme inhibitors: Are their benefits a class effect or do individual agents differ?","volume":"10","author":"Sica","year":"2001","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R12-5-20240902","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10286-018-0572-5","article-title":"The renin-angiotensin system in cardiovascular autonomic control: Recent developments and clinical implications","volume":"29","author":"Miller","year":"2019","journal-title":"Clin Auton Res"},{"key":"R13-5-20240902","first-page":"52","article-title":"Anemia in heart failure-From guidelines to controversies and challenges","volume":"20","author":"S\u00eerbu","year":"2018","journal-title":"Anatol J Cardiol"},{"key":"R14-5-20240902","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3317\/jraas.2002.046","article-title":"The pharmacokinetics and pharmacodynamics of angiotensin receptor blockers in endstage renal disease","volume":"3","author":"Sica","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R15-5-20240902","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1524-6175.2007.06296.x","article-title":"Antihypertensive medications and anemia","volume":"9","author":"Sica","year":"2007","journal-title":"J Clin Hypertens (Greenwich"},{"key":"R16-5-20240902","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000507272","article-title":"Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes","volume":"51","author":"Marathias","year":"2020","journal-title":"Am J Nephrol"},{"key":"R17-5-20240902","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1161\/CIRCULATIONAHA.105.549121","article-title":"Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure","volume":"112","author":"van der Meer","year":"2005","journal-title":"Circulation"},{"key":"R18-5-20240902","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.10.038","article-title":"Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction","volume":"45","author":"Ishani","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R19-5-20240902","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/clc.4960281003","article-title":"Anemia in heart failure--A concise review","volume":"28","author":"Vasu","year":"2005","journal-title":"Clin Cardiol"},{"key":"R20-5-20240902","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CNP66011","article-title":"Clinical characteristics of chronic kidney disease patients with and without diabetes: A subanalysis of the PAERI study","volume":"66","author":"Lorber","year":"2006","journal-title":"Clin Nephrol"},{"key":"R21-5-20240902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/937398","article-title":"Heart failure in patients with chronic kidney disease: A systematic integrative review","volume":"2014","author":"Segall","year":"2014","journal-title":"Biomed Res Int"},{"key":"R22-5-20240902","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/sj.jhh.1001352","article-title":"Angiotensin II receptor antagonists role in arterial hypertension","volume":"16","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"2002","journal-title":"J Hum Hypertens"},{"key":"R23-5-20240902","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.amjmed.2015.08.025","article-title":"Practical approach to detection and management of chronic kidney disease for the primary care clinician","volume":"129","author":"Vassalotti","year":"2016","journal-title":"Am J Med"},{"key":"R24-5-20240902","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"R25-5-20240902","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan Ramipril or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"The New England Journal of Medicine"},{"key":"R26-5-20240902","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jchf.2017.08.023","article-title":"Anemia in heart failure: Still relevant?","volume":"6","author":"Grote Beverborg","year":"2018","journal-title":"JACC Heart Fail"},{"key":"R27-5-20240902","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijcard.2010.12.016","article-title":"Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure","volume":"157","author":"Sandek","year":"2012","journal-title":"Int J Cardiol"},{"key":"R28-5-20240902","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"CONFIRM-HF investigators.Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"R29-5-20240902","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3111\/13696998.2015.1029491","article-title":"Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden","volume":"18","author":"Hofmarcher","year":"2015","journal-title":"J Med Econ"},{"key":"R30-5-20240902","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/eurjhf\/hfq165","article-title":"Iron deficiency and anaemia in heart failure: Understanding the FAIR-HF trial","volume":"12","author":"Gonz\u00e1lez-Costello","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R31-5-20240902","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R32-5-20240902","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2147\/TCRM.S61551","article-title":"The role of erythropoietin stimulating agents in anemic patients with heart failure: Solved and unresolved questions","volume":"10","author":"Palazzuoli","year":"2014","journal-title":"Ther Clin Risk Manag"}],"container-title":["Heart Views"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/HEARTVIEWS.HEARTVIEWS_211_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:08:10Z","timestamp":1787166490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/HEARTVIEWS.HEARTVIEWS_211_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/heartviews.heartviews_211_20","relation":{},"ISSN":["1995-705X"],"issn-type":[{"value":"1995-705X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}